Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

<div>In vivo biodistribution of [68Ga]Ga-DOTA-E(cRGDfK)2 in normal mice. Data were calculated as a percentage of the injected dose per gram of organs (%ID/g) at 30, 60, and 90 min postinjection. Values are mean ± standard deviation (n = 3 per group).</div>

Contrast Media & Molecular Imaging

fig9

Figure 9

Figure 9: Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

Figure 9 | Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer 